M

Targeted Therapy

Home  >  Complementary Medicine  >  Targeted Therapy

Immunocine Cancer Center

Dendritic Cell Immunotherapy Immunocine offers a next-generation dendritic cell immunotherapy developed by Dr. Matt Halpert and his team at Baylor College of Medicine. This innovative approach...

Progressive Medical Center

The Progressive Medical Center, an Integrative Functional Medicine and Health and Wellness Center located in Dunwoody, GA, represents a paradigm of complementary medicine. The center, led by Dr....

IOZK Immun-Onkologisches Zentrum Köln

Based in Cologne, Germany, the IOZK Immun-Onkologisches Zentrum Köln is renowned for its research and application of immunological therapies for cancer. They focus on vaccine therapies and have a...

Williams Cancer Institute

Located in Cabo San Jose, Mexico, the Williams Cancer Institute is at the forefront of advanced cancer treatments. The institute’s approach is characterized by its minimally invasive yet...

Is There A Cancer Conspiracy?

Does a cure for cancer already exist? The American Cancer Society (ACS) recently conducted a telephone survey and found some disturbing trends. In particular, its pollsters discovered that 27...

Hydrazine Sulfate Trials and Tribulations

Where are your randomized controlled trials? … is the usual response to proponents of alternative cancer therapies. And, indeed, there are few rigorous clinical studies of most unconventional...

Why Precision Oncology Is Not The Solution

Personalized Medicine Precision oncology is defined as the “molecular profiling of tumors to identify targetable alterations.” Scientists have designed targeted drugs to attack mutations in...

Keytruda: Toxic, Expensive and Not So Effective

Best Selling Cancer Drug in 2019 Keytruda® (pembrolizumab) is toxic, expensive, and not as effective as one would wish. But at $7.2 billion, it was the best-selling cancer drug in 2019. At the...

Down Goes Dr. Baselga

Sandpiper Trial On Saturday, June 2, 2018, Dr. José Baselga, MD, Physician-in-chief of Memorial Sloan-Kettering Cancer Center was enthused about the results of the SANDPIPER trial. He told the...

FDA Reverses Approval of Avastin

Stunning Reversal In a stunning rebuke to the former director of the Food and Drug Administration (FDA), an advisory panel has recommended removing the approval of the drug Avastin (bevacizumab)...

Imatinib (Gleevec) for Chronic Myeloid Leukemia

Glee Over GleevecAfter the announcement of herceptin, work accelerated on many other targeted agents for cancers. In that same year, clinical trials began for a new drug for chronic myeloid...

The Disturbing Case of José Baselga

Conflict of InterestThe best-publicized case of conflict of interest in cancer involved José Baselga, MD, Ph.D., the Physician-in-Chief, i.e., the top doctor of Memorial Sloan-Kettering Cancer...

Selumetinib: The Selling of a Drug

Targeted Therapies    I attended the 2013 annual meeting of the American Society of Clinical Oncology (ASCO). Some of my journalistic colleagues there were excited about the latest findings...

The Amazing Case of Dr Wortman

Precision Medicine Let's start with Precision Medicine at its very best. This was the inspiring story of Dr. Lukas Wortman, MD, which helped catapult the topic into public consciousness. In 2012,...

Shadows Fall on Anti-Angiogenic Drugs

The Main Hope of Conventional OncologyFor the past dozen years, drugs that inhibit the growth of new blood vessels—a strategy called anti-angiogenesis—have been the main hope of conventional...

What Are Surrogate Endpoints?

Progression Free SurvivalThe NCI Dictionary of Cancer Terms defines a surrogate endpoint in clinical trials as: “...an indicator or sign used in place of another to tell if a treatment works....

The Case of Xalkori (crizotinib)

Conflicts of InterestAlmost every study of a new cancer drug is riddled with conflicts of interest. Let us focus on one of these drugs, crizotinib (Xalkori®). But we could conduct the same sort...

The Strange Case of Xalkori

A Great Success Story?Let us look at a drug that is considered one of the great success stories of the precision medicine approach, Xalkori (crizotinib). The story of Xalkori illustrates some of...

Is Chemotherapy Toxic?

Considering Toxicity Let us consider the question of toxicity, which we discussed in articles on specific trials of so-called “Precision Medicine’ for cancer. When targeted therapy was first...

The Pitfalls of Progression-Free Survival (PFS)

A Hypothetical LookLet us consider the pitfalls of using progression-free survival (PFS) as a “surrogate endpoint” by showing how someone could extend patients’ PFS, without actually helping them...

Biases in Clinical Trials

Assessing the Effects of a New DrugThere are various ways in which the sponsors of a clinical trial can exaggerate the effects of a new drug on progression-free survival (PFS). This can be done...

Herceptin – or Deception?

Pivotal Results? Two studies published in October 2005 in the New England Journal of Medicine have sparked a triumphant reaction from both the media and the medical profession. The studies...

Vemurafenib (Zelboraf®)

Vemurafenib (Zelboraf®): A Cause for Celebration? An item that is causing “celebration” among melanoma patients is the experimental drug vemurafenib. Data on this was presented at ASCO’s annual...

Cancer Stem Cells Identified

Cancer Stem Cells (CSCs) May Be Responsible for Malignancy [Note: This article was originally a report on the first identification of cancer stem cells (CSCs) in a solid tumor. But breast cancer...

Lymphoma and Adcetris®

 Drug for Hodgkin’s Lymphoma Elsewhere I wrote that an FDA advisory panel had recommended that the agency approve a new drug for Hodgkin lymphoma, brentuximab. In August 2011, the FDA gave...

Stunning Avastin Reversal

A Revocation In a stunning rebuke to a former director of the Food and Drug Administration (FDA), an advisory panel has recommended removing the approval of the drug Avastin® (bevacizumab) for...

Lung Cancer and Xalkori

Companion Diagnostics In August 2011, the FDA approved Pfizer’s new anticancer pill, crizotinib (Xalkori®). The approval was unusual in several respects. Approval was for a very specific...

Brentuximab-Adcetris-Injection-50-mg-vial

FDA Panel Approves New Drug for Lymphoma

FDA Panel Approves New Drug for Lymphoma A key panel of the Food and Drug Administration (FDA) has voted to recommend accelerated approval for the injectable drug brentuximab vedotin (Adcetris®)....

CellSearch – Tests for Cancer

Noninvasive Blood Testing This is an exciting time for noninvasive blood tests for cancer. Several biotech companies are vying to become the first to introduce a “liquid biopsy.” This is a blood...

Research and Resources for Melanoma

Adjuvant Therapy for Cutaneous Malignant Melanoma In a phase III trial, certain advanced malignant melanoma (MM) patients were given nivolumab (Opdivo®). They had increased progression-free...

Avastin® and Ovarian Cancer – Any Benefit?

Top Cancer Drug Bevacizumab (Avastin®) is, economically speaking, the top cancer drug in the world. Sales in 2010 topped $6.9 billion. One of the reasons for this financial success has been its...

ImClone’s Troubles

Two Billion Dollar Molecule In July 2002, the drug cetuximab (Erbitux®) was featured on the cover of Business Week. The New York Times called it the "two billion dollar molecule." Wall Street...